Skip to main content
Erschienen in: Rheumatology International 6/2019

25.04.2019 | Observational Research

Cancer incidence in familial Mediterranean fever patients: a retrospective analysis from central Anatolia

verfasst von: Emre Bilgin, Ömer Dizdar, Deniz Can Güven, Serdar Ceylan, Özge Aybi, Büşra Fırlatan, Rıza Can Kardaş, Tolga Yıldırım, Mutlu Kadir Hayran, Umut Kalyoncu, Seza Özen

Erschienen in: Rheumatology International | Ausgabe 6/2019

Einloggen, um Zugang zu erhalten

Abstract

Although chronic inflammation has been associated with increased cancer risk in various disease including hepatitis or inflammatory bowel disease, a lower incidence of cancer has been reported recently in familial Mediterranean fever (FMF) which is an auto-inflammatory disease with persistent inflammation. We have assessed cancer incidence among FMF patients with or without amyloidosis to investigate this hypothesis. We performed a retrospective review of FMF patients, diagnosed and treated in Hacettepe University hospitals between 2001 and 2018. We identified patients from the hospital medical records using the ICD-10 code for FMF. We collected data on demographic and clinical features, drug history, the presence of amyloidosis and subsequent diagnosis of cancer. The expected cancer incidence was estimated using age- and gender-specific standardized incidence rates (SIRs) in comparison with the general Turkish population according to Turkish National Cancer Registry data at 2014. Total of 3899 FMF patients (120 patients had also amyloidosis) were included. Median age was 22 and 56% were females. Thirty-eight patients were diagnosed with cancer during 100,283 person-years of follow-up. The most common cancer was breast cancer in females (7/28 patients) and leukemia (2/10 patients) in males. The overall cancer incidence among patients with FMF was significantly lower in both males {SIR 0.42 [95% confidence interval; (CI) 0.21–0.75], p = 0.019} and females [SIR 065 (95% CI 0.44–0.93), p = 0.002]. The overall cancer incidence among patients with FMF and amyloidosis was [SIR 1.21 (95% CI 0.49–2.52), p = 0.73] without gender difference. Cancer incidence was significantly lower in FMF patients compared with the general Turkish population. We found no increased cancer incidence in FMF patients having amyloidosis. Possible underlying mechanisms need to be explained.
Literatur
1.
Zurück zum Zitat Heller H, Kariv J, Sherf L, Sohar E (1955) Familial Mediterranean fever. Harefuah 48(5):91–94PubMed Heller H, Kariv J, Sherf L, Sohar E (1955) Familial Mediterranean fever. Harefuah 48(5):91–94PubMed
2.
Zurück zum Zitat Soylemezoglu O, Kandur Y, Gonen S, Duzova A, Ozcakar ZB, Fidan K, Yalcinkaya F (2016) Familial Mediterranean fever gene mutation frequencies in a sample Turkish population. Clin Exp Rheumatol 34(6 Suppl 102):97–100PubMed Soylemezoglu O, Kandur Y, Gonen S, Duzova A, Ozcakar ZB, Fidan K, Yalcinkaya F (2016) Familial Mediterranean fever gene mutation frequencies in a sample Turkish population. Clin Exp Rheumatol 34(6 Suppl 102):97–100PubMed
5.
Zurück zum Zitat Doerr W (1985) Cohnheim's inflammation doctrine and the current debate. Zentralblatt fur allgemeine Pathologie u pathologische Anatomie 130(4):299–306PubMed Doerr W (1985) Cohnheim's inflammation doctrine and the current debate. Zentralblatt fur allgemeine Pathologie u pathologische Anatomie 130(4):299–306PubMed
7.
Zurück zum Zitat Koizumi T, Kamata T, Nakamura M, Sugawa Y, Mitsuya N (1970) Case of primary cancer of the liver developing in the course of chronic hepatitis. Nihon rinsho Jpn J Clin Med 28(2):316–319 Koizumi T, Kamata T, Nakamura M, Sugawa Y, Mitsuya N (1970) Case of primary cancer of the liver developing in the course of chronic hepatitis. Nihon rinsho Jpn J Clin Med 28(2):316–319
8.
Zurück zum Zitat Johnson TM, Orr TG (1948) Carcinoma of the colon secondary to chronic ulcerative colitis. Am J Dig Dis 15(1):21–23CrossRefPubMed Johnson TM, Orr TG (1948) Carcinoma of the colon secondary to chronic ulcerative colitis. Am J Dig Dis 15(1):21–23CrossRefPubMed
16.
Zurück zum Zitat Brenner R, Ben-Zvi I, Shinar Y, Liphshitz I, Silverman B, Peled N, Levy C, Ben-Chetrit E, Livneh A, Kivity S (2018) Familial Mediterranean fever and incidence of cancer: an analysis of 8,534 Israeli patients with 258,803 person-years. Arthritis Rheumatol 70(1):127–133. https://doi.org/10.1002/art.40344 CrossRefPubMed Brenner R, Ben-Zvi I, Shinar Y, Liphshitz I, Silverman B, Peled N, Levy C, Ben-Chetrit E, Livneh A, Kivity S (2018) Familial Mediterranean fever and incidence of cancer: an analysis of 8,534 Israeli patients with 258,803 person-years. Arthritis Rheumatol 70(1):127–133. https://​doi.​org/​10.​1002/​art.​40344 CrossRefPubMed
17.
Zurück zum Zitat Turkish National Cancer Registry (TNCR) (2014). https://hsgm.saglik.gov.tr/tr/kanser-istatistikleri/yillar/495-2014-yılı-türkiye-kanser-istatistikleri.html. Accessed 1 July 2018 Turkish National Cancer Registry (TNCR) (2014). https://​hsgm.​saglik.​gov.​tr/​tr/​kanser-istatistikleri/​yillar/​495-2014-yılı-türkiye-kanser-istatistikleri.​html.​ Accessed 1 July 2018
20.
Zurück zum Zitat Brito-Zeron P, Kostov B, Fraile G, Caravia-Duran D, Maure B, Rascon FJ, Zamora M, Casanovas A, Lopez-Dupla M, Ripoll M, Pinilla B, Fonseca E, Akasbi M, de la Red G, Duarte-Millan MA, Fanlo P, Guisado-Vasco P, Perez-Alvarez R, Chamorro AJ, Morcillo C, Jimenez-Heredia I, Sanchez-Berna I, Lopez-Guillermo A, Ramos-Casals M (2017) Characterization and risk estimate of cancer in patients with primary Sjogren syndrome. J Hematol Oncol 10(1):90. https://doi.org/10.1186/s13045-017-0464-5 CrossRefPubMedPubMedCentral Brito-Zeron P, Kostov B, Fraile G, Caravia-Duran D, Maure B, Rascon FJ, Zamora M, Casanovas A, Lopez-Dupla M, Ripoll M, Pinilla B, Fonseca E, Akasbi M, de la Red G, Duarte-Millan MA, Fanlo P, Guisado-Vasco P, Perez-Alvarez R, Chamorro AJ, Morcillo C, Jimenez-Heredia I, Sanchez-Berna I, Lopez-Guillermo A, Ramos-Casals M (2017) Characterization and risk estimate of cancer in patients with primary Sjogren syndrome. J Hematol Oncol 10(1):90. https://​doi.​org/​10.​1186/​s13045-017-0464-5 CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Bernatsky S, Ramsey-Goldman R, Labrecque J, Joseph L, Boivin JF, Petri M, Zoma A, Manzi S, Urowitz MB, Gladman D, Fortin PR, Ginzler E, Yelin E, Bae SC, Wallace DJ, Edworthy S, Jacobsen S, Gordon C, Dooley MA, Peschken CA, Hanly JG, Alarcon GS, Nived O, Ruiz-Irastorza G, Isenberg D, Rahman A, Witte T, Aranow C, Kamen DL, Steinsson K, Askanase A, Barr S, Criswell LA, Sturfelt G, Patel NM, Senecal JL, Zummer M, Pope JE, Ensworth S, El-Gabalawy H, McCarthy T, Dreyer L, Sibley J, St Pierre Y, Clarke AE (2013) Cancer risk in systemic lupus: an updated international multi-centre cohort study. J Autoimmun 42:130–135. https://doi.org/10.1016/j.jaut.2012.12.009 CrossRefPubMedPubMedCentral Bernatsky S, Ramsey-Goldman R, Labrecque J, Joseph L, Boivin JF, Petri M, Zoma A, Manzi S, Urowitz MB, Gladman D, Fortin PR, Ginzler E, Yelin E, Bae SC, Wallace DJ, Edworthy S, Jacobsen S, Gordon C, Dooley MA, Peschken CA, Hanly JG, Alarcon GS, Nived O, Ruiz-Irastorza G, Isenberg D, Rahman A, Witte T, Aranow C, Kamen DL, Steinsson K, Askanase A, Barr S, Criswell LA, Sturfelt G, Patel NM, Senecal JL, Zummer M, Pope JE, Ensworth S, El-Gabalawy H, McCarthy T, Dreyer L, Sibley J, St Pierre Y, Clarke AE (2013) Cancer risk in systemic lupus: an updated international multi-centre cohort study. J Autoimmun 42:130–135. https://​doi.​org/​10.​1016/​j.​jaut.​2012.​12.​009 CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Silman AJ, Petrie J, Hazleman B, Evans SJ (1988) Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20 year follow up study. Ann Rheum Dis 47(12):988–992CrossRefPubMedPubMedCentral Silman AJ, Petrie J, Hazleman B, Evans SJ (1988) Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20 year follow up study. Ann Rheum Dis 47(12):988–992CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Yunos NM, Beale P, Yu JQ, Strain D, Huq F (2010) Studies on combinations of platinum with paclitaxel and colchicine in ovarian cancer cell lines. Anticancer Res 30(10):4025–4037PubMed Yunos NM, Beale P, Yu JQ, Strain D, Huq F (2010) Studies on combinations of platinum with paclitaxel and colchicine in ovarian cancer cell lines. Anticancer Res 30(10):4025–4037PubMed
26.
Zurück zum Zitat La Regina G, Bai R, Coluccia A, Famiglini V, Pelliccia S, Passacantilli S, Mazzoccoli C, Ruggieri V, Sisinni L, Bolognesi A, Rensen WM, Miele A, Nalli M, Alfonsi R, Di Marcotullio L, Gulino A, Brancale A, Novellino E, Dondio G, Vultaggio S, Varasi M, Mercurio C, Hamel E, Lavia P, Silvestri R (2014) New pyrrole derivatives with potent tubulin polymerization inhibiting activity as anticancer agents including hedgehog-dependent cancer. J Med Chem 57(15):6531–6552. https://doi.org/10.1021/jm500561a CrossRefPubMedPubMedCentral La Regina G, Bai R, Coluccia A, Famiglini V, Pelliccia S, Passacantilli S, Mazzoccoli C, Ruggieri V, Sisinni L, Bolognesi A, Rensen WM, Miele A, Nalli M, Alfonsi R, Di Marcotullio L, Gulino A, Brancale A, Novellino E, Dondio G, Vultaggio S, Varasi M, Mercurio C, Hamel E, Lavia P, Silvestri R (2014) New pyrrole derivatives with potent tubulin polymerization inhibiting activity as anticancer agents including hedgehog-dependent cancer. J Med Chem 57(15):6531–6552. https://​doi.​org/​10.​1021/​jm500561a CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Ridker PM, MacFadyen JG, Thuren T, Everett BM, Libby P, Glynn RJ (2017) Effect of interleukin-1beta inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet (London, England) 390(10105):1833–1842. https://doi.org/10.1016/s0140-6736(17)32247-x CrossRef Ridker PM, MacFadyen JG, Thuren T, Everett BM, Libby P, Glynn RJ (2017) Effect of interleukin-1beta inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet (London, England) 390(10105):1833–1842. https://​doi.​org/​10.​1016/​s0140-6736(17)32247-x CrossRef
31.
Zurück zum Zitat Raaschou P, Soderling J, Turesson C, Askling J, Group AS (2018) Tumor necrosis factor inhibitors and cancer recurrence in Swedish patients with rheumatoid arthritis: a nationwide population-based cohort study. Ann Intern Med 169(5):291–299. https://doi.org/10.7326/M17-2812 CrossRef Raaschou P, Soderling J, Turesson C, Askling J, Group AS (2018) Tumor necrosis factor inhibitors and cancer recurrence in Swedish patients with rheumatoid arthritis: a nationwide population-based cohort study. Ann Intern Med 169(5):291–299. https://​doi.​org/​10.​7326/​M17-2812 CrossRef
41.
Zurück zum Zitat Shouval DS, Biswas A, Kang YH, Griffith AE, Konnikova L, Mascanfroni ID, Redhu NS, Frei SM, Field M, Doty AL, Goldsmith JD, Bhan AK, Loizides A, Weiss B, Yerushalmi B, Yanagi T, Lui X, Quintana FJ, Muise AM, Klein C, Horwitz BH, Glover SC, Bousvaros A, Snapper SB (2016) Interleukin 1beta mediates intestinal inflammation in mice and patients with interleukin 10 receptor deficiency. Gastroenterology 151(6):1100–1104. https://doi.org/10.1053/j.gastro.2016.08.055 CrossRefPubMedPubMedCentral Shouval DS, Biswas A, Kang YH, Griffith AE, Konnikova L, Mascanfroni ID, Redhu NS, Frei SM, Field M, Doty AL, Goldsmith JD, Bhan AK, Loizides A, Weiss B, Yerushalmi B, Yanagi T, Lui X, Quintana FJ, Muise AM, Klein C, Horwitz BH, Glover SC, Bousvaros A, Snapper SB (2016) Interleukin 1beta mediates intestinal inflammation in mice and patients with interleukin 10 receptor deficiency. Gastroenterology 151(6):1100–1104. https://​doi.​org/​10.​1053/​j.​gastro.​2016.​08.​055 CrossRefPubMedPubMedCentral
43.
Zurück zum Zitat Drexler SK, Bonsignore L, Masin M, Tardivel A, Jackstadt R, Hermeking H, Schneider P, Gross O, Tschopp J, Yazdi AS (2012) Tissue-specific opposing functions of the inflammasome adaptor ASC in the regulation of epithelial skin carcinogenesis. Proc Natl Acad Sci USA 109(45):18384–18389. https://doi.org/10.1073/pnas.1209171109 CrossRefPubMed Drexler SK, Bonsignore L, Masin M, Tardivel A, Jackstadt R, Hermeking H, Schneider P, Gross O, Tschopp J, Yazdi AS (2012) Tissue-specific opposing functions of the inflammasome adaptor ASC in the regulation of epithelial skin carcinogenesis. Proc Natl Acad Sci USA 109(45):18384–18389. https://​doi.​org/​10.​1073/​pnas.​1209171109 CrossRefPubMed
46.
Zurück zum Zitat Daley D, Mani VR, Mohan N, Akkad N, Pandian G, Savadkar S, Lee KB, Torres-Hernandez A, Aykut B, Diskin B, Wang W, Farooq MS, Mahmud AI, Werba G, Morales EJ, Lall S, Wadowski BJ, Rubin AG, Berman ME, Narayanan R, Hundeyin M, Miller G (2017) NLRP3 signaling drives macrophage-induced adaptive immune suppression in pancreatic carcinoma. J Exp Med 214(6):1711–1724. https://doi.org/10.1084/jem.20161707 CrossRefPubMedPubMedCentral Daley D, Mani VR, Mohan N, Akkad N, Pandian G, Savadkar S, Lee KB, Torres-Hernandez A, Aykut B, Diskin B, Wang W, Farooq MS, Mahmud AI, Werba G, Morales EJ, Lall S, Wadowski BJ, Rubin AG, Berman ME, Narayanan R, Hundeyin M, Miller G (2017) NLRP3 signaling drives macrophage-induced adaptive immune suppression in pancreatic carcinoma. J Exp Med 214(6):1711–1724. https://​doi.​org/​10.​1084/​jem.​20161707 CrossRefPubMedPubMedCentral
Metadaten
Titel
Cancer incidence in familial Mediterranean fever patients: a retrospective analysis from central Anatolia
verfasst von
Emre Bilgin
Ömer Dizdar
Deniz Can Güven
Serdar Ceylan
Özge Aybi
Büşra Fırlatan
Rıza Can Kardaş
Tolga Yıldırım
Mutlu Kadir Hayran
Umut Kalyoncu
Seza Özen
Publikationsdatum
25.04.2019
Verlag
Springer Berlin Heidelberg
Erschienen in
Rheumatology International / Ausgabe 6/2019
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-019-04311-x

Weitere Artikel der Ausgabe 6/2019

Rheumatology International 6/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.